The TSG101 gene, identi®ed through insertional mutagenesis, is localized in a region that exhibits LOH in human cancers, suggesting that TSG101 might be a tumor suppressor gene. Numerous studies have then shown the presence of abnormal transcripts in various tumors which appear to result from aberrant splicing of the gene, rather than from intragenic deletions. Moreover, many studies demonstrated that these aberrantly spliced transcripts were not found in matched normal tissues. We have analysed TSG101 transcripts in 85 breast cancer samples and found that abnormal splicing of the gene is tightly correlated with tumor grade and p53 mutation. In addition, stress induced the appearance of these abnormal transcripts in primary lymphocytes. Hence, TSG101 splicing defects, while unrelated to the oncogenic process per se, could re¯ect the cellular environment of the tumor cells. The proposed role of stress and hypoxia to select p53 mutant cells could account for the tight association with p53 status.
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Keywords: TSG101; p53; stress, tumor grading; splicing; breast cancer The mouse tsg101 gene was discovered by functional knockout in ®broblasts leading to cell transformation and to the ability to form metastatic tumors in nude mice (Li and Cohen, 1996) . It was thus suggested that tsg101 could act to suppress malignant cell growth. The human homologue TSG101 was then isolated and mapped to 11p15 a known region of LOH in a number of malignant tumors (BesnardGuerin et al., 1996; Lisuka et al., 1995; Winqvist et al., 1995) . Li et al. (1997) reported the presence of truncated transcripts observed by RT ± PCR in seven of 15 human primary breast cancers, while normal transcripts were found in matched normal breast. Moreover, initial reports of truncated PCR products of genomic DNA suggested the presence of intragenic deletions of TSG101 gene in many spontaneous human breast cancers. However, later studies of direct Southern blot on breast tumor samples probed with TSG101 cDNA failed to demonstrate any genomic rearrangements, including some with truncated transcripts (Chang et al., 1999; Gayther et al., 1997; Lee and Feinberg, 1997; Oh et al., 1998; Steiner et al., 1997) . Detailed analysis of these truncated transcripts demonstrates that they result from aberrant splicing on a limited number of cryptic splice acceptor/donor sites (Gayther et al., 1997; Lee and Feinberg, 1997; Wagner et al., 1998) . Finally, aberrantly spliced TSG101 transcripts were also found in normal tissues (Carney et al., 1998; Chang et al., 1999; Lee and Feinberg, 1997; Lin et al., 1998a; Willeke et al., 1998) .
Altogether, these data demonstrate that TSG101 is not a tumor suppressor gene. Nevertheless, this splicing defect might be enhanced during transformation or cellular states associated to tumor growth. In that sense, TSG101 splicing abnormalities were consistently and speci®cally found in breast, prostate or gastrointestinal cancers compared to adjacent normal tissues (Lin et al., 1998b; Sun et al., 1997) . Finally, the appearance of smaller TSG101 transcripts was greatly increased in primary lymphocytes stressed upon ageing by incubation at room temperature (Gayther et al., 1997) . Hence, abnormal TSG101 splicing, while unrelated to the oncogenic process, could re¯ect some feature of cancer development. To address this hypothesis we have tested, in a large series of breast cancers, whether TSG101 aberrant splicing would correlate with other cellular or molecular markers.
Results and discussion
Eighty-®ve breast cancers including one medullary-, six invasive lobular-and 78 invasive ductal carcinomas were analysed. Tumor samples, snap-frozen less than 10 min after surgical removal, were obtained for RNA extraction at the time of diagnosis from patients admitted to Saint-Louis Hospital. Tissue sections containing more than 70% tumor cells were homogenized and RNA were immediately isolated according to Chomczynski and Sacchi (1987) and stored at 7808C. TSG101 transcripts were analysed by RT ± PCR exactly as described by Li et al. (1997) . Detection of p53 mutations was performed with a functional assay that tests the transcriptional competence of human p53 expressed in yeast (Flaman et al., 1995; Waridel et al., 1997) . This test was reported to detect over 90% of the reported mutations. Histological tumor grading was determined according to the criteria of Bloom and Richardson (1957) .
In 23 (27%) of the 85 cancers studied, TSG101 truncated transcripts were observed in addition to the full-length transcript found in each of the 85 cancers ( Figure 1a ). These shorter RT ± PCR fragments varied in size and abundance compared to the full-length product. Note, however, that the abnormal fragment was in much lower abundance than the full-length one, as previously shown (Chang et al., 1999; Gayther et al., 1997; Lee and Feinberg, 1997; Li et al., 1997; Sun et al., 1997; Willeke et al., 1998) . The speci®city of the shorter PCR fragments was veri®ed by Southern blot hybridization using a cDNA fragment internal to the primers as a probe (Figure 1b) . Sequence analysis showed that the abnormal fragment in Figure 1a , lane 3 (550 bp, deletion nt 133 ± 730) was previously described in other cancer samples (Chang et al., 1999; Gayther et al., 1997; Lee and Feinberg, 1997; Sun et al, 1997; Willeke et al., 1998) . Southern blot analysis of the ®rst round PCR products allowed the detection of few truncated forms, demonstrating that truncation is not an artifact of the nested PCR procedure (not shown). Using this same technique, we failed to detect any truncated transcripts in fresh lymphocytes isolated from ten of these breast cancer patients with and without abnormalities in their tumors and in three normal breast tissue samples. Hence, with the level of sensitivity of our assay, abnormal splicing products of this gene are far more abundant in the neoplastic tissue than in the normal blood cells and tissue.
Analysing the p53 status, we found that 35% of the cancers (30 of 85) were p53 mutated, consistent with the literature (Coles et al., 1992; Saitoh et al., 1994) . As summarized in Table 1A , truncated TSG101 transcripts were strongly correlated with p53 mutation (P=0.006) since 14 of the 23 cancers with truncated TSG101 transcripts were p53 mutated. Note that p53 mutations did not result from abnormal splicing of the p53 gene, since RT ± PCR always ampli®ed p53 at the expected size in tumors with an altered TSG101 pro®le (not shown).
Aberrant TSG101 transcripts were even more strongly correlated with high histological tumor grade (P=0.0003) (Table 1B) since 20 of the 23 were grade III, the three others being grade II. p53 mutation was also strongly correlated with high histological tumor grade (P50.0001) (Table 1C) , as previously reported Southern blot analysis of the RT ± PCR products from human breast cancer samples. Four breast cancer samples from (a) were hybridized using a cDNA probe comprising nt 141 ± 1222 (GenBank, access number U82130). (c) Southern blot analysis of the RT ± PCR products from stressed primary lymphocytes. Blood was obtained from normal human volunteers after informed consent. Mononuclear cells obtained by centrifugation (Ficoll-Hypaque), were cultured in RPMI with 20% FCS, either without or with 1 mg/ml PHA-M. After a 24 h culture, CoCl 2 (100 mM ®nal concentration) was added or not, and cells further cultured for 18 h. Then the cells were washed and cultured for 6 h in the same media without CoCl 2 . Cells were pelleted and RNA were extracted. Note that stress (absence of PHA or hypoxia) induces cell aberrant mRNAs (arrows) A: TSG101 aberrant transcripts versus p53 mutation; B: TSG101 aberrant transcripts versus histological tumor grade; C: p53 mutation versus histological tumor grade; FL=full length, Trunc=truncated transcripts; P=Chi-square test TSG101 tightly correlated with tumor grading in breast cancer E Turpin et al (Knowles et al., 1994; Sato et al., 1997; Silvestrini et al., 1996; Valgardsdottir et al., 1997) . No signi®cant association of TSG101 status was found with other clinical features such as lymph node invasion, metastasis, in¯ammatory tumors, etc. Altogether, our data indicate that abundant abnormal TSG101 transcripts strongly correlate with both p53 mutation and high histological tumor grade. A previous report demonstrated the presence of aberrantly spliced TSG101 transcripts in ageing lymphocytes (Gayther et al., 1997) . To address the role of stress in the generation of truncated TSG101 transcripts, primary lymphocytes were cultured without or with a mitogen (PHA) and/or CoCl 2 which mimic hypoxia, (Figure 1c) . Under stress conditions, absence of PHA and/or presence of CoCl 2 , fragments originating from spliced RNAs were generated. Similar results were obtained with hypoxia instead of CoCl 2 (not shown). Hence in normal cells, stress induction can induce defects in TSG101 splicing. This is likely the basis for the appearance of spliced transcripts in ageing lymphocytes (Gayther et al., 1997) and points to the importance of the state of normal tissues prior to RNA extraction.
Our results, together with those of others (Carney et al., 1998; Lee and Feinberg, 1997; Li et al., 1997) , suggest that there is some association between neoplastic processes and an increase in abnormal TSG101 splicing. The extreme importance of the thresholds in the detection of abnormal splicing between tumor and normal cells likely precludes its use as a prognosis indicator. Yet, the very tight correlation between aberrant TSG101 mRNA and prognosis such as grade and p53 status, strongly suggests that this is a non random process. Stress conditions, including hypoxia, is well known as an inducer of DNA breaks in fragile chromosomal sites (Coquelle et al., 1998) . In this respect, note that viral insertions are frequently observed in fragile sites and that TSG101 was originally identi®ed by retroviral mutagenesis (Li and Cohen, 1996) . TSG101 might be located in a fragile DNA site.
Several other interpretations to our ®ndings can be proposed. Either the defect in TSG101 splicing is controlled by p53 disfunction, which would be compatible with its occurrence in SV40 T transformed prostatic cells (not shown). Note in this respect that oncogenes such as Spi or WT1 were previously shown to interfere with splicing process (Hallier et al., 1996; Lamond, 1995; Larsson et al., 1995) . However, observing that a signi®cant proportion of TSG101 abnormalities are found in cancers that do not harbour p53 mutation, does not favour this hypothesis. Alternatively, TSG101 abnormal transcripts are independent of p53 mutation but are present with greater frequency in cancers with a poor histological grading, re¯ecting poor local growth conditions. The generation of truncated TSG101 transcripts under stress conditions favours this hypothesis. Indeed, it has been proposed that in tumors hypoxia provides a strong selective pressure for apoptotic variants, in particular cells harboring p53 mutations (Graeber et al., 1996) . This could account for the tight association of aberrant TSG101 transcripts with both p53 status and tumor grade.
